Added to YB: 2026-09-15
Pitch date: 2026-09-12
VANI [neutral]
Vivani Medical, Inc.
Author Info
No bio for this author
Company Info
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases.
Market Cap
$114.6M
Pitch Price
$1.26
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.90
P/E
-3.61
EV/Sales
N/A
Sector
Health Care Equipment and Supplies
Category
special_situation
Biotech Conference Coverage day 4 session 3 - Vivani Medical, Inc.
VANI (quick overview): Vivani Medical is developing a removable, six-month semaglutide implant intended to improve persistence versus weekly injections or daily pills. Management reported that prior exenatide implant data supported sustained-release device behavior but did not establish obesity efficacy for NPM-139. The M&A thesis is that a major incretin company could value this format. Vivani expects November pharmacokinetic and safety data from fully enrolled SLIM-1; key risks are stable human exposure, efficacy, tolerability, implant practicality, reimbursement and patient preference amid improving alternatives.
Read full article (2 min)